NASDAQ:KNDL
$11.43   - 0.62
Jul 2, 2009 4:03 PM ET
Corporate Headquarters
441 Vine Street
Suite 500
Cincinnati, OH 45202
Tel: 1 800 733 1572 (in US only)
Tel: +1 513 381 5550
Fax: +1 513 381 5870

Investor Relations

Company profile

Established: 1981
Corporate Headquarters: Cincinnati, Ohio
Employees: 4,122 (as of March 31, 2009)

Locations:
North America: Ann Arbor, Michigan; Chicago, Illinois; Cincinnati, Ohio; Cranford, New Jersey; Durham, North Carolina; Los Angeles, California; Morgantown, West Virginia; Old Lyme, Connecticut; Rockville, Maryland; Wilmington, North Carolina; Canada: Toronto, Ontario; Europe: Brussels, Belgium; Sofia, Bulgaria; Prague, Czech Republic; Camberley, England; Ely, England; Maidenhead, England; Lyon, France; Paris, France; Munich, Germany; Tel-Aviv, Israel; Milan, Italy; Saronno, Italy; Utrecht, The Netherlands; Warsaw, Poland; Bucharest, Romania; Moscow, Russia; Edinburgh, Scotland; Glasgow, Scotland; Barcelona, Spain; Madrid, Spain; Uppsala, Sweden; Asia/Pacific: Melbourne, Australia; Sydney, Australia; Ahmedabad, India; New Delhi, India; Kuala Lumpur, Malaysia; Manila, Philippines; Singapore, Singapore; Bangkok, Thailand; and through a joint venture in Beijing, China; Hong Kong, China; Shanghai, China; Latin America: Buenos Aires, Argentina; Rio de Janeiro, Brazil; Santiago, Chile; Bogota, Colombia; Mexico City, Mexico; Lima, Peru. Africa: Johannesburg, South Africa.



Business Overview
Kendle is among the world's leading, global publicly held clinical research organizations. We deliver innovative and robust clinical development solutions - from First-in-Human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share. Kendle competes and has competitive advantages in five core competencies, including:

  • Early Stage, which provides comprehensive global services, from First-in-Human through Phase IIa/proof-of-concept studies, including patient recruitment, with world-leading psychopharmacology expertise
  • Clinical Development, which provides Phase II-III clinical research services to biopharmaceutical companies across a broad spectrum of therapeutic areas
  • Regulatory Affairs, which provides strategic clinical development planning, regulatory submissions, clinical trial regulatory affairs, nonclinical consulting, CMC development and pharmacovigilance/safety services
  • Biometrics, which provides clinical data management, biostatistics and eClinical (EDC) services
  • Late Phase, which provides Phase IIIB/IV studies; health economics, patient-reported outcomes and outcomes research; product/disease registries and observational studies; and scientific events and medical education services

Kendle's customer focus, global scale and innovative technology offer a strategic advantage in bringing life-enhancing and life-saving new medicines to market.

Global Scale
Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa. Approximately 54 percent of Kendle's workforce is based outside North America, as is 47 percent of our first quarter revenue. In addition, we have conducted research and provided clinical services in more than 100 countries.

Therapeutic Expertise
Kendle contributes to the development, approval and life cycle management of innovative therapies for a broad range of medical conditions. We have more than 25 years of experience in serving customers both large and small and with a diversity of compounds, which means that our expertise spans every major therapeutic area. We are focused on growing our Phase I-IV clinical development expertise in the top five therapeutic areas expected to represent nearly 70 percent of drug sales by 2013; cardiology, oncology, antibiotics and antivirals, diabetes and arthritis/inflammation.1 Oncology continues to be among the largest therapeutic areas for Kendle. We continue to see strong growth in sales for programs in these areas and we expect them to continue to be growth drivers for our business going forward.

Proprietary Software Solutions: TrialWare®
Kendle's proprietary suite of software products, TrialWare®, enables clinical trial data to be processed faster through automated workflow, parallel processing and standardization. The TrialWare® family of technology includes TrialBase®, our database management system; TrialWatch®, our global project management information system; TriaLine®, our interactive voice response patient randomization system; TrialWeb®, our Web-based communications and information sharing tool; TriAlert®, our coding enhancement feature, TrialMD®, our investigator feasibility and information management system and TrialEASTM our Web-base, electronic adjudication system.

1. Source: Cowen and Company, "Therapeutic Categories Outlook," March 2009
 
 
Quotes delayed at least 20 minutes. Information provided by eSignal.